Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

about

Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.

P2860

Q35450340-FFE3AECA-1353-4E2C-A3C6-27539390ACB6

P2860

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

Item

http://www.wikidata.org/entity/Q39362495

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

@en

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

@nl

type

Item

label

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

@en

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

@nl

prefLabel

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

@en

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

@nl

P1476

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

@en

P2093

Gan Weidong

http://www.w3.org/2001/XMLSchema#string

Guo Hongqian

http://www.w3.org/2001/XMLSchema#string

Jia Ruipeng

http://www.w3.org/2001/XMLSchema#string

Qu Feng

http://www.w3.org/2001/XMLSchema#string

Sun Xitai

http://www.w3.org/2001/XMLSchema#string

Yan Xiang

http://www.w3.org/2001/XMLSchema#string

P2860

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.

Is there something other than imatinib mesilate in therapeutic options for GIST?

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Response evaluation of gastrointestinal stromal tumors.

Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.

Surgical management of rectal gastrointestinal stromal tumors.

Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.

P304

1697-1701

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.167

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23971501

http://www.w3.org/2001/XMLSchema#string

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

about

P2860

P2860

Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698